GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Liabilities-to-Assets

TME Pharma NV (FRA:0N6A) Liabilities-to-Assets : 0.47 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. TME Pharma NV's Total Liabilities for the quarter that ended in Jun. 2024 was €1.38 Mil. TME Pharma NV's Total Assets for the quarter that ended in Jun. 2024 was €2.94 Mil. Therefore, TME Pharma NV's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2024 was 0.47.


TME Pharma NV Liabilities-to-Assets Historical Data

The historical data trend for TME Pharma NV's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Liabilities-to-Assets Chart

TME Pharma NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.07 0.28 0.54 1.24 1.12

TME Pharma NV Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 1.24 1.05 1.12 0.47

Competitive Comparison of TME Pharma NV's Liabilities-to-Assets

For the Biotechnology subindustry, TME Pharma NV's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TME Pharma NV's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Liabilities-to-Assets falls into.


;
;

TME Pharma NV Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

TME Pharma NV's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=2.785/2.491
=1.12

TME Pharma NV's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2024 is calculated as

Liabilities-to-Assets (Q: Jun. 2024 )=Total Liabilities/Total Assets
=1.375/2.942
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TME Pharma NV  (FRA:0N6A) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


TME Pharma NV Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


TME Pharma NV Business Description

Traded in Other Exchanges
Address
Max-Dohrn-Street 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines